Indeed, emerging evidence has shown that VPS34 can modulate the basal activity of mTOR complex 1 (mTORC1) in animal models and the glycogen synthetase kinase 3 (GSK3) pathway in breast cancer patients treated with AKT inhibitors [33]. The gene discussed is AKT1; the disease is breast carcinoma.